Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic control of p53 activity in regulatory T cells maintains their identity to prevent inflammation.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Avoidance of MAIT cells is an essential determinant of <i>Listeria</i> monocytogenes pathogenesis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Intratumoral T<sub>reg</sub> cell ablation elicits NK cell-mediated control of CD8 T cell-resistant tumors.

Science immunology·2026
Same author

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics.

Science (New York, N.Y.)·2026
Same author

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.

Cancer discovery·2026
Same author

Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity.

Science advances·2026

Related Experiment Video

Updated: Jun 3, 2026

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Intratumoral Regulatory T cell Ablation Mediates Tumor Control Systemically without Autoimmunity.

Alissa Bockman1, Chenyu Zhang2, Brenna Gittins1

  • 1University of California, Berkeley Berkeley United States.

Cancer Research
|June 2, 2026
PubMed
Summary
This summary is machine-generated.

Targeting regulatory T cells (Tregs) within tumors, not systemically, enhances antitumor immunity and controls cancer growth. This approach leverages CD4+ T cells for potent tumor suppression without causing autoimmunity.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 3, 2026

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Regulatory T cells (Tregs) infiltrate tumors, suppressing anti-tumor immunity and correlating with poor patient survival.
  • Systemic Treg depletion is problematic due to their role in preventing autoimmunity.
  • Targeting Tregs specifically within the tumor microenvironment is a potential therapeutic strategy.

Purpose of the Study:

  • To investigate the efficacy of intratumoral (IT) regulatory T cell (Treg) depletion in controlling tumor growth.
  • To elucidate the mechanisms by which IT Treg ablation mediates anti-tumor responses.
  • To assess the potential for translating this strategy using clinically relevant agents.

Main Methods:

  • Intratumoral delivery of diphtheria toxin (DT) in Foxp3DTR mice to selectively deplete Tregs within tumors.
  • Analysis of immune cell populations (Tregs, CD4+ T cells, CD8+ T cells, cDCs) within tumors.
  • Assessment of tumor growth and control in primary and distant secondary tumors.
  • Investigation of Treg-mediated suppression of dendritic cell function.
  • Evaluation of an anti-CCR8 antibody for IT Treg depletion.

Main Results:

  • Intratumoral Treg depletion significantly reduced Treg frequencies in tumors, leading to potent tumor control without systemic autoimmunity.
  • Tumor control was primarily mediated by CD4+ T cells, with CD8+ T cells contributing when CD4+ T cells were absent.
  • Conventional dendritic cells (cDCs), including cDC1s and cDC2s, were crucial for tumor clearance.
  • Distant secondary tumors were also controlled following IT Treg ablation in the primary tumor.
  • Mechanistically, tumor Tregs were found to suppress anti-tumor T cell responses by impairing antigen acquisition and presentation by cDC2s.
  • An anti-CCR8 antibody demonstrated similar Treg-depleting effects and tumor control.

Conclusions:

  • Intratumoral Treg ablation is a viable strategy for enhancing anti-tumor immunity and controlling cancer progression.
  • This approach effectively leverages CD4+ T cell-mediated responses and avoids systemic autoimmunity.
  • The findings support the development of targeted Treg depletion therapies, such as using anti-CCR8 antibodies, for cancer treatment.